Statistical flag only — not an accusation of fraud
⚠️ This provider averages 847 services per working day — physically unusual for an individual practitioner
Based on 1.1M total services over 5 years (250 working days/year). Learn about impossible service volumes →
This provider's $13.7M in total Medicare payments ranks in the 99th percentile of Hematology-Oncology providers nationally.
Averaging 847 services per working day raises questions about billing patterns.
Medicare payments to this provider grew 605% from 2019 to 2023.
This provider has been statistically flagged with a risk score of 68/100. Statistical flags are not accusations of fraud.
AI-generated analysis based on Medicare payment data.
Notable: Payments increased 422% in 2020
Year-over-year payment surges can indicate changes in practice volume, new services, or billing pattern shifts.
Average per-service amounts submitted by the provider compared to what Medicare actually paid — the gap represents the markup.
| Year | Avg Submitted | Avg Paid | Markup Ratio | Gap per Service | Total Payments | Services | Beneficiaries |
|---|---|---|---|---|---|---|---|
| 2019 | $39.31 | $12.08 | 3.25x | $27.23 | $596.7K | 49.4K | 44 |
| 2020 | $42.86 | $13.71 | 3.13x | $29.15 | $3.1M | 226.9K | 68 |
| 2021 | $37.66 | $11.91 | 3.16x | $25.75 | $2.7M | 230.5K | 65 |
| 2022 | $38.57 | $11.75 | 3.28x | $26.82 | $3.1M | 263.1K | 73 |
| 2023 | $48.33 | $14.54 | 3.32x | $33.79 | $4.2M | 289.0K | 76 |
| Code | Description | Services | Payments | Avg/Service | Markup |
|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 66.2K | $2.7M | $41.11 | 3.41x |
| J9299 | Injection, nivolumab, 1 mg | 67.8K | $1.6M | $23.00 | 3.48x |
| J1561 | Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg | 28.0K | $989.3K | $35.29 | 2.41x |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | 26.1K | $939.4K | $35.99 | 2.36x |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | 742 | $738.6K | $995.42 | 3.01x |
| J9041 | Injection, bortezomib, 0.1 mg | 19.6K | $548.6K | $27.99 | 3.39x |
| J0897 | Injection, denosumab, 1 mg | 31.6K | $524.5K | $16.62 | 2.41x |
| Q5115 | Injection, rituximab-abbs, biosimilar, (truxima), 10 mg | 10.7K | $476.2K | $44.34 | 3.84x |
| A9607 | Lutetium lu 177 vipivotide tetraxetan, therapeutic, 1 millicurie | 2.4K | $460.2K | $191.74 | 2.35x |
| J9312 | Injection, rituximab, 10 mg | 5.5K | $404.9K | $73.09 | 2.60x |
| J0129 | Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | 7.7K | $329.3K | $42.91 | 2.56x |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | 3.3K | $287.3K | $86.25 | 2.32x |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | 2.9K | $271.6K | $93.38 | 3.11x |
| J9022 | Injection, atezolizumab, 10 mg | 3.1K | $187.6K | $60.13 | 2.53x |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 1.1K | $181.4K | $159.72 | 1.00x |
| J2796 | Injection, romiplostim, 10 micrograms | 2.4K | $151.7K | $63.51 | 2.20x |
| J9035 | Injection, bevacizumab, 10 mg | 2.3K | $144.9K | $63.01 | 2.54x |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 20.8K | $139.4K | $6.70 | 3.28x |
| A9596 | Gallium ga-68 gozetotide, diagnostic, (illuccix), 1 millicurie | 123 | $139.2K | $1.1K | 2.43x |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | 3.1K | $128.4K | $41.03 | 2.44x |
This provider submits charges 3.23 times higher than what Medicare actually pays.
A markup ratio of 3.23x means for every $100 Medicare pays, this provider initially charges $323. This is higher than the national average.
Always verify provider credentials and location before scheduling appointments. This data reflects Medicare payments and may not include all practice locations.
Other Hematology-Oncology providers in AR for peer comparison.
| Provider | Location | Total Payments | Status |
|---|---|---|---|
| Kamal Patel, M.D. | Little Rock, AR | $58.7M | ⚠️ Flagged |
| Balagopalan Nair, M.D. | Little Rock, AR | $54.5M | ⚠️ Flagged |
| Eric Schaefer, M.D. | Fayetteville, AR | $35.5M | ✓ Clear |
| Thomas Sneed, M.D. | Little Rock, AR | $34.7M | ✓ Clear |
| Lawrence Mendelsohn, MD | Little Rock, AR | $34.6M | ⚠️ Flagged |
Share this provider's Medicare payment information
Last Updated: February 2026 (data through 2023, the latest CMS release)
Note: All data is from publicly available Medicare records. OpenMedicare is an independent journalism project not affiliated with CMS.
Believe this data is inaccurate? Dispute this data